EASYSPRAY Quick Reference Guide
For detailed information please contact your local representative.
Baxter, Artiss, and Easyspray are trademarks of Baxter International Inc., its subsidiaries or affiliates.
ROI/MG24/13-0001e September 2013
WARNINGS AND PRECAUTIONS
Caution: Pressurised gas supply must be between 3.5 and 7 bar (50-100 psi).
Caution: DO NOT connect to an oxygen source. Failure to follow these instructions can lead to explosion, which could result in serious injury or death.
Prior to operation make sure that the pressure range of the device is adjusted to the range specified in the appropriate spray set instructions for use.
Caution: Spraying into enclosed body cavities requires appropriate safety measures to make sure that the above mentioned risks will be avoided.
NOTE: Do not use with rechargeable batteries. The use of accessories of other manufacturers is not permitted.
Any application of pressurised gas may be associated with a potential risk of air or gas embolism, tissue rupture or air or gas entrapment with
compression, which may be life threatening if the product is sprayed incorrectly
Precautions
For ARTISS Solutions for Sealant
• In open-wound: when applying sprayable fibrin solutions for sealant using a pressure regulator device, the maximum pressure should be 2.0 bar (28.5 psi).
The product should be sprayed at a distance at least 10 cm from the tissue surface.
• Spray application should only be used if it is possible to accurately judge the spray distance as recommended by the manufacturer. Do not spray closer than
the recommended distances.
• Prior to applying sprayable fibrin solutions for sealant, the surface area of the wound should only be dried using standard techniques (eg, intermittent
application of compresses, swabs, use of suction devices).
• Blood pressure, pulse rate, oxygen saturation and end tidal CO2 should be monitored closely when spraying fibrin solutions for sealant using a pressure
regulator device, because of the possibility of occurrence of air or gas embolism.
• Regulators should be used in line with manufacturer recommendations and the SmPC and Instruction for Use.
• ARTISS is recommended for subcutaneous use only. ARTISS is not recommended for laparoscopic use.
CAUTION BOX
When applying ARTISS using a spray device be sure to use a pressure and a distance from tissue within the ranges recommended by the manufacturer as follows:
Recommended pressure, distance and devices for spray application of ARTISS
Surgery Spray set to be used
Applicator tips
to be used
Pressure regulator to be used
Recommended distance
from target tissue
Recommended spray pressure
Open wound of subcutaneous tissue
TISSEEL / ARTISS Spray Set n.a. EASYSPRAY
10 – 15 cm
1.5-2.0 bar
(21.5-28.5 psi)
TISSEEL / ARTISS Spray Set 10 pack n.a. EASYSPRAY
When spraying the ARTISS, changes in blood pressure, pulse, oxygen saturation and end tidal CO2 should be monitored because of the possibility of occurrence of air or gas embolism.
PRESCRIBING INFORMATION – ARTISS
(Please consult the Summary of Product Characteristics before prescribing)
Name and composition: ARTISS Solutions for Sealant – one prefilled double chamber syringe containing Sealer
Protein Solution (with aprotinin) deep frozen in one chamber and Thrombin Solution (with calcium chloride) deep
frozen in the other chamber. Sealer Protein Solution contains 91mg/ml human fibrinogen (clottable protein) and 3000
KIU/ml aprotinin. Thrombin Solution contains 4 IU/ml human thrombin and 40μmol/ml calcium chloride. Presentations of 1, 2 or 5ml in each chamber resulting in total volume of 2ml, 4ml or 10ml of total volume of product ready for
use. Contains human factor XIII co-purified with human fibrinogen in a range of 0.6 – 5 IU/ml. Indication: Hospital
use only. A tissue glue to adhere / seal subcutaneous tissue in plastic, reconstructive and burn surgery, replacement
or adjunct to sutures or staples. Adjunct to haemostasis on subcutaneous tissue surfaces. Dosage and Route: The
use of ARTISS is restricted to experienced surgeons who have been trained in the use of ARTISS. For epilesional
use. Dose individualised and governed by indication, application methods and number of applications. Guide – 1
pack ARTISS 2ml sufficient for an area at least 10 cm2. Avoid excess granulation by applying only a thin layer. Surface of the wound should be as dry as possible. Side effects: See summary of product characteristics for detail.
Risk of anaphylactic reaction. Intravascular injection may lead to life-threatening thromboembolic events. Hypersensitivity or allergic reactions. Pruritus, skin graft failure Precautions: Caution applying ARTISS using pressurised gas,
not to be used with Easy Spray / Spray Set system in enclosed body areas - risk of air or gas embolism, tissue rupture or gas entrapment. Use spray device pressure within manufacturers recommended range, not exceeding 2.0
bars. Do not spray closer than 10-15 cm from tissue surface. Monitor blood pressure, pulse, oxygen saturation, end
tidal CO2 for possibility of occurrence of air or gas embolism. Not indicated for use where a fast clotting sealant is
required, especially in cardiovascular surgery. Not for use in neurosurgery or gastrointestinal or vascular anastomoses. Excessive clot thickness may interfere with efficacy and wound healing. Care to prevent adhesion at undesired
sites. Signs of hypersensitivity include hives, urticaria, tightness of chest, wheezing, hypotension, anaphylaxis. Risk
of anaphylaxis increased if previous exposure to aprotinin. In event of hypersensitivity or anaphylaxis discontinue
use and remove polymerised product from surgical site. Oxycellulose containing preparations may reduce ARTISS
efficacy. Infectious diseases due to transmission of infective agents cannot be totally excluded. Use of ARTISS
and batch number should be recorded in patients’ notes. Carefully evaluate in patients with allergies to bovine
proteins. Contra-indications: Not indicated to replace sutures intended to close surgical wound. Not for treatment
of massive and brisk arterial or venous bleeding. Not for intravascular use. Hypersensitivity to active substances
or excipients. Interactions: Avoid solutions containing alcohol, iodine and heavy metals. Overdose: No cases of
overdose have been reported. Legal Category: POM Marketing Authorisation Number and Holder: ARTISS – PA
167/131/001, Baxter Healthcare Limited, Caxton Way, Thetford, Norfolk. IP24 3SE. Date of Preparation: March 2013
Any adverse event relating to Baxter products should be reported to Baxter Healthcare directly by calling
01-206-5500 and asking for the Quality Department.
Baxter Healthcare encourages healthcare professionals to continue to be vigilant and to report suspected
adverse reactions with ARTISS to the Irish Medicines Board (online at www.imb.ie, telephone 01-6764971
or using the yellow card system).
Baxter Healthcare Ltd
Unit 7 Deansgrange Business Park
Blackrock
Co. Dublin
Tel: 01 2065500
Fax: 01 2065555
www.baxterhealthcare.ie